Just a reminder to think about who is in the driver’s seat when this increased risk of death issue with injectable checkpoint inhibitors gets brought up by FDA and other jurisdictions. What happens if they need to remain in IV mode while competing with generics potentially being brought to market with L?; ). Any reason certain entities would want to crush the stock price now?; (. Best wishes.
Market Data 
Markets 
AI
